(Reuters) – The U.S. Food and Drug Administration on Thursday declined to approve Atara Biotherapeutics’ cancer therapy, chemically called tabelecleucel.
The company was seeking approval for the therapy to treat patients with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)
